Risk Register Template for Pharmaceutical Company

Standard Operating Procedure: Pharmaceutical Risk Register Management & Lifecycle Validation

1. Document Control Block

• Document ID: SOP-TR-QA-4091
• Effective Date: October 24, 2023
• Version: 3.2
• Review Cadence: Annual / Post-Audit
• Regulatory Baseline: 21 CFR Part 11, ICH Q9 (Quality Risk Management), EU Annex 11

---

2. Executive Summary & Purpose

This Standard Operating Procedure (SOP) defines the institutional requirements for initiating, maintaining, reviewing, and retiring Risk Registers within Template Registry’s pharmaceutical and biomanufacturing ecosystems. The purpose is to establish a standardized, audit-ready framework for identifying, evaluating, mitigating, and documenting quality, safety, data integrity, and supply chain risks in compliance with global regulatory agencies (FDA, EMA, ICH).

---

3. Scope & Prerequisites

Scope

• Applies to all Research, Development, Clinical Manufacturing, Commercial Production, and IT/Automation systems managed or hosted by Template Registry.

Prerequisites

• Software Systems: validated Enterprise Quality Management System (EQMS), 21 CFR Part 11 compliant Risk Management database (e.g., Veeva Vault, TrackWise, or approved MS Excel template v3.2 with cryptographic checksums).
• Required Training:
  • TR-SOP-901: cGMP Fundamentals & Data Integrity
  • TR-SOP-4091: Advanced ICH Q9 Risk Assessment Methodologies (FMEA, PHA, HACCP)
• Personal Protective Equipment (PPE): Not applicable (administrative/digital procedure).

---

4. Roles & Responsibilities (RACI Matrix)

Legend: R = Responsible, A = Accountable, C = Consulted, Informed = I

---

5. Step-by-Step Procedure

Phase 1: Risk Identification & Initiation

• 1.1 Initiate a new Risk Register entry in the validated EQMS upon identifying a process deviation, design change, regulatory update, or scheduled annual review.
• 1.2 Assign a unique alphanumeric identifier using the syntax: RR-[YYYY]-[System/Process Code]-[Sequential Number] (e.g., RR-2023-BIO-042).
• 1.3 Document the Risk Statement using the structural format: "If [Hazard/Event occurs], then [Potential Consequence/Impact on Product Quality, Patient Safety, or Data Integrity], resulting in [Clinical/Business Impact]."
• 1.4 Categorize the risk domain: Quality, Safety, Compliance, Supply Chain, or Data Integrity.

Phase 2: Risk Evaluation & Prioritization (Initial Assessment)

• 2.1 Convene an assessment panel consisting of the System Owner, Risk Analyst, and relevant SMEs.
• 2.2 Evaluate the Severity (S) of the potential consequence on a 1–5 scale (1 = Negligible, 5 = Critical/Catastrophic patient safety impact) per ICH Q9 guidelines.
• 2.3 Evaluate the Occurrence (O) likelihood on a 1–5 scale (1 = Extremely Unlikely/Historical zero, 5 = Frequent/Continuous).
• 2.4 Evaluate the Detectability (D) on a 1–5 scale (1 = Certain to be detected prior to impact, 5 = Undetectable prior to impact/patient exposure).
• 2.5 Calculate the initial Risk Priority Number (RPN) or Risk Score: $\text{RPN} = \text{Severity (S)} \times \text{Occurrence (O)} \times \text{Detectability (D)}$.
• 2.6 Classify the initial risk tier based on numerical thresholds:
  • High Risk (RPN 80–125): Immediate mandatory containment and mitigation plan.
  • Medium Risk (RPN 30–79): Formal mitigation required within 30 calendar days.
  • Low Risk (RPN 1–29): Acceptable without further action; monitor via routine change control.

Phase 3: Mitigation Strategy & Implementation

• 3.1 Formulate risk reduction strategies targeting either Reduction of Occurrence, Reduction of Severity, or Improvement of Detectability.
• 3.2 Assign specific, actionable mitigation tasks with distinct owners and hard target completion dates.
• 3.3 Log all mitigation action items as linked change controls or CAPAs (Corrective and Preventive Actions) within the EQMS.
• 3.4 Execute mitigation actions under strict change management protocols.

Phase 4: Residual Risk Evaluation & Verification

• 4.1 Re-evaluate Severity, Occurrence, and Detectability after full implementation of mitigation measures to establish the Residual Risk Score.
• 4.2 Verify that the Residual Risk has dropped to an acceptable level (Target: Low Risk tier, or Medium Risk with documented toxicological/quality justification).
• 4.3 Verify that no New Risks (Secondary Risks) were introduced by the mitigation measures.
• 4.4 Route the completed risk assessment package to Quality Assurance for formal review and digital signature.

Phase 5: Periodic Review & Archival

• 5.1 Schedule automated review triggers in the EQMS based on the designated risk tier (High: Quarterly; Medium: Semi-Annually; Low: Annually).
• 5.2 Archive the Risk Register entry upon system retirement or process obsolescence, ensuring data retention for a minimum of 11 years (or product lifecycle + 1 year, whichever is longer).

---

6. Quality Assurance & Pro-Tips

Best Practices

• Multidisciplinary Consensus: Never perform a risk assessment in isolation. Always include cross-functional SMEs (Microbiology, Validation, QA) to prevent blind spots.
• Dynamic Updates: Treat the Risk Register as a living document. Update scores immediately following any deviation, OOS (Out of Specification) result, or audit finding.
• Traceability: Maintain bidirectional traceability links between the Risk Register, User Requirements Specifications (URS), and Validation Protocols (IQ/OQ/PQ).

Common Pitfalls to Avoid

• Conflating S, O, and D: Ensure Detectability strictly measures the ability of current controls to catch the failure, not the probability that the failure will happen.
• Vague Risk Statements: Avoid ambiguous entries like "Equipment failure." Use precise failure modes like "CIP (Clean-in-Place) temperature sensor drift leading to inadequate microbial bioburden reduction."

Metric Thresholds

• Mitigation Closure Rate: $\ge 95%$ of mitigation actions completed on or prior to the target due date.
• High-Risk Resolution Time: 100% of High-Risk items must have an active, QA-approved mitigation plan within 5 business days of identification.

---

7. Frequently Asked Questions (FAQ)

Q1: What happens if a residual risk remains in the "High" category after all feasible mitigations have been applied?

A1: The risk must be escalated immediately to the Site Quality Head and the Global Quality Council. A formal Benefit-Risk Analysis (BRA) must be authored and approved by Executive Management and QA before the process or product can be released for commercial distribution or clinical use.

Q2: Can spreadsheets (e.g., Microsoft Excel) be used as a standalone Risk Register?

A2: Standalone unvalidated spreadsheets are prohibited for GMP-impact processes. If an offline template is utilized during early-stage R&D, it must be stored in a secured, version-controlled document repository with audit trails enabled, and migrated into a validated EQMS prior to Phase II clinical trials.

Q3: How are scoring discrepancies between cross-functional reviewers resolved?

A3: The highest assigned score among the reviewers must be adopted by default for Severity and Occurrence to ensure a conservative, patient-centric compliance posture. If consensus cannot be reached, the Quality Assurance representative holds ultimate veto and decision-making authority.